Our collective appetite for weight loss drugs has become pretty much insatiable over the past few years. It’s thought that around 1.5 million people in the UK are on GLP-1 agonist medications to curb ...
Morning Overview on MSN
An experimental weight-loss pill just matched the blockbuster injections in a trial — letting patients skip the needle and take a daily tablet instead
For the millions of Americans injecting themselves weekly with Wegovy, Ozempic, Mounjaro, or Zepbound, the promise of a ...
Everyday Health on MSN
How weight loss pills have changed — and what that means for safety
Though recent data shows a meaningful decrease in the U.S. adult obesity rate (37 percent in 2025 compared with a record high of 39.9 percent in 2022), the need for obesity treatments is still ...
The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ...
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...
Much to the relief of the needle-shy, the Food and Drug Administration has just approved a second oral GLP-1 drug, following the release of the semaglutide Wegovy pill in January. But this new tablet, ...
Popular weight-loss and type 2 diabetes drugs such as Wegovy and Ozempic are typically taken as self-administered injections—a bearable albeit unpleasant jab to the abdomen or thigh. But drug ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The launch this week of an oral pill version of Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results